CX3CR1 and breast carcinoma: CRISPR deletion of CX3CR1 or its blockade in human tumor lines of PDAC, breast cancer, prostate cancer, bladder cancer and glioblastoma results in a decrease in the ability of tumor cells to migrate and metastasize (34, 37).